Here's why Pediatrix Medical Group (MD) is a strong growth stock
This article from MSN suggests that Pediatrix Medical Group (MD) is a strong growth stock. It does not provide further details or analysis within the given content.
MD SEC Filings - Pediatrix Medical Group, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Pediatrix Medical Group (Ticker: MD) SEC filings, including annual 10-K reports, quarterly 10-Q reports, 8-K material events, and insider trading forms. It lists recent filings from August and July 2025, detailing their nature (e.g., insider trading, quarterly earnings, material events) and their Rhea-AI Impact and Sentiment. The page also offers FAQs about the number and recency of filings, along with various financial rankings and stock data for Pediatrix Medical Group.
Pediatrix Medical Group (MD) Q1 Earnings and Revenues Surpass Estimates
Pediatrix Medical Group (MD) reported strong Q1 2026 earnings, beating Zacks Consensus Estimates for both earnings per share and revenue. The company posted earnings of $0.44 per share against an estimated $0.37, and revenues of $476.2 million, surpassing the $467.05 million estimate. Despite outperforming expectations, the stock has slightly underperformed the S&P 500 year-to-date, and currently holds a Zacks Rank #3 (Hold).
Here's Why You Should Add Pediatrix Medical to Your Portfolio Now
Pediatrix Medical (MD) is positioned for growth due to strong cash collections, a favorable payer mix, higher patient acuity in neonatology, and strategic acquisitions. The company's shares have risen 9.7% year-to-date, contrasting with an industry decline. Despite its potential
Weis family trust tied to Pediatrix (MD) director sells 36,028 shares
A trust associated with Pediatrix Medical Group director Shirley A. Weis sold 36,028 shares of common stock in an open-market transaction for a weighted average price of $23.75 per share, totaling approximately $855,665. The Weis Family Trust, for which Shirley A. Weis and her husband serve as trustees, now holds no Pediatrix shares, though Shirley A. Weis directly retains 18,623 shares. This sale is likely to be viewed as a negative signal given the insider selling activity.
Pediatrix (NYSE: MD) director McEachin reports 22,854-share stock gift
Pediatrix Medical Group (NYSE: MD) director Thomas McEachin reported two bona fide gifts totaling 22,854 shares of company common stock on May 13, 2026. These non-cash charitable-style transfers included one gift of 11,427 shares to a trust where he and his spouse are trustees and beneficiaries, and another 11,427 shares from directly held stock. Following these transactions, McEachin indirectly owns 66,073 shares through the trust and directly owns 7,196 shares.
Pediatrix Medical Group (MD) Is Up 13.7% After Beating EPS and Reaffirming EBITDA Outlook - Has The Bull Case Changed?
Pediatrix Medical Group (MD) reported strong first-quarter 2026 results, surpassing EPS expectations and reaffirming its full-year adjusted EBITDA outlook of US$280 million to US$300 million. This performance, driven by pricing and payer mix despite volume declines, reinforces the company's investment narrative, which hinges on stable demand and resilient cash flows in hospital-based neonatal and maternal care. While the shareholder approval of an expanded incentive compensation plan aims to retain talent, investors should remain cautious about potential future reimbursement and regulatory pressures.
Pediatrix Medical Group (NYSE: MD) files Form 144 to resell 36,028 shares
Pediatrix Medical Group (NYSE: MD) has filed a Form 144 notice through Robert W. Baird & Co. to propose the resale of 36,028 restricted common shares. These shares are tied to compensatory vesting events from 2021, 2023, 2024, and 2025. A Form 144 permits a holder to comply with resale conditions, but the filing itself does not confirm that the shares have been sold.
Pediatrix Medical Group (MD) Is Up 13.7% After Beating EPS and Reaffirming EBITDA Outlook - Has The Bull Case Changed?
Pediatrix Medical Group (MD) reported strong first-quarter 2026 results, beating EPS expectations and reaffirming its full-year adjusted EBITDA outlook. This positive performance was driven by pricing and payer mix benefits, despite modest volume declines. The company's investment narrative now hinges on its ability to convert stable demand into resilient cash flows amid potential reimbursement and regulatory pressures.
[Form 4] Pediatrix Medical Group, Inc. Insider Trading Activity
Mary Ann E. Moore, EVP and General Counsel of Pediatrix Medical Group, Inc., reported a gift transfer of 40,826 shares of company stock to a family trust on May 11, 2026. Following this transaction, she directly holds 108,410 shares and indirectly holds 93,424 shares through the trust, disclaiming beneficial interest in the trust-held shares except for her pecuniary interest. This Form 4 filing details the insider trading activity, showing a neutral impact and sentiment according to Rhea-AI.
Pediatrix. (MD) Reports Q1 EPS Beat
Pediatrix Medical Group, Inc. (NYSE:MD) reported stronger-than-expected Q1 2026 results, with adjusted EPS of 44 cents against an estimate of 38 cents, and revenue of $476 million, surpassing the $465.82 million consensus. The company reaffirmed its FY26 adjusted EBITDA outlook of $280M-$300M. Analysts at Jefferies and Truist adjusted their price targets for MD following the positive performance.
Pediatrix (NYSE: MD) director awarded 7,196 restricted shares
Pediatrix Medical Group (NYSE: MD) director Sylvia Jean Young was awarded 7,196 restricted shares of common stock on May 7, 2026, as an annual equity award under the company's 2008 Incentive Compensation Plan. These shares were granted at no cash cost and will vest on May 7, 2027. Following this transaction, Young directly holds 47,814 shares of Pediatrix common stock.
Pediatrix Medical Group (MD) director receives 7,196-share restricted stock award
Pediatrix Medical Group director Michael A. Rucker was granted 7,196 restricted shares of common stock as an annual equity award, which will vest on May 7, 2027. This grant was provided at no cash cost under the company's Amended and Restated 2008 Incentive Compensation Plan. Following this transaction, Rucker directly holds 66,297 shares of Pediatrix Medical Group common stock.
5 Best Small Cap US Stocks to Buy
This article lists the 5 best small-cap US stocks to buy, with a detailed focus on Pediatrix Medical Group, Inc. (NYSE:MD). It highlights Pediatrix Medical Group's strong Q1 2026 results, positive analyst ratings, and its role as a leading provider of pediatric healthcare services. The article also includes a promotional section for a "game-changing AI stock."
15 Best Small Cap Stocks to Buy for 10x Potential
This article, part of a larger list, highlights Pediatrix Medical Group, Inc. (NYSE: MD) as a top small-cap stock with 10x potential. It details the company's financial results for Q1 2026, including EPS, net income, adjusted EBITDA, and net revenue, and notes a price target increase by Mizuho. Pediatrix Medical Group provides physician services, focusing on neonatal, maternal fetal, and other pediatric subspecialty care.
Earnings call transcript: Pediatrix Medical Group beats Q1 2026 expectations
Pediatrix Medical Group (MD) exceeded analyst expectations in Q1 2026 with an EPS of $0.44 and revenue of $476 million, outperforming forecasts. Despite an initial stock dip, it rebounded in premarket trading and has shown a strong 61.8% return over the past year. Management reaffirmed its full-year adjusted EBITDA guidance and highlighted strategic expansions, strong pricing growth, and investments in clinical quality.
Pediatrix (NYSE: MD) director receives 7,196 restricted shares in equity award
Pediatrix Medical Group (NYSE: MD) director Guy P. Sansone was granted 7,196 restricted shares as an annual equity award, vesting on May 7, 2027. This grant was provided at no cash cost under the company's Amended and Restated 2008 Incentive Compensation Plan. Following this transaction, Sansone directly holds 86,944 shares of Pediatrix Medical Group common stock, an increase reflecting routine stock-based compensation rather than an open-market purchase.
Earnings call transcript: Pediatrix Medical Group beats Q1 2026 expectations
Pediatrix Medical Group exceeded Q1 2026 expectations with an EPS of $0.44 against a forecast of $0.38, and revenue of $476 million against $465.68 million. Despite an initial stock dip, it rebounded in premarket trading and maintains strong full-year guidance for adjusted EBITDA between $280 million and $300 million. The company attributes its success to strategic growth, effective expense management, and a focus on care quality, with leadership appointments aimed at enhancing data-driven clinical excellence.
Earnings call transcript: Pediatrix Medical Group beats Q1 2026 expectations By Investing.com
Pediatrix Medical Group exceeded analyst expectations in Q1 2026 with an EPS of $0.44 and revenue of $476 million, driven by strategic revenue growth and efficient expense management. Despite a slight initial stock dip, it rebounded in premarket trading and has shown a 61.8% return over the past year. Management reaffirmed full-year adjusted EBITDA guidance, emphasizing investments in clinical quality and the potential for expansion through hospital partnerships and teleservices.
A Look At Pediatrix Medical Group (MD) Valuation After Its Strong First Quarter Earnings Update
Pediatrix Medical Group (MD) is attracting investor attention after a strong first-quarter earnings report, showing higher sales, net income, and EPS compared to the previous year, resulting in significant short-term stock price gains. Despite a strong one-year return and a low P/E ratio, most analyses suggest the stock is overvalued at $21.33, primarily due to portfolio restructuring and rising salary costs. The article suggests investors should conduct further research into the company's financial health to reconcile conflicting valuation signals.
Pediatrix Medical Group Q4 Profitability Turnaround Tests Market Skepticism On Slow Growth
Pediatrix Medical Group (MD) reported a return to profitability in Q4 2025, with net income of US$33.7 million and basic EPS of US$0.40, following a net loss in Q3 2024. While the company demonstrates "high quality earnings" with four consecutive quarters of positive net income in 2025 and trades at a low P/E, market skepticism persists due to slow growth forecasts of 0.3% for earnings and 4% for revenue, significantly below US market averages. This valuation gap and modest growth challenge the outlook despite the improved financials.
Pediatrix Medical Group (MD) adds 8M shares to incentive plan at 2026 meeting
Pediatrix Medical Group, Inc. shareholders approved an amendment to its 2008 Incentive Compensation Plan, adding 8,000,000 common shares for equity awards. This decision was made at the 2026 Annual Shareholders’ Meeting, where all director nominees were elected, PricewaterhouseCoopers LLP was ratified as the independent auditor, and executive compensation for 2025 was approved on an advisory basis. The meeting had a strong quorum with 77,330,139 shares represented out of 83,072,104 outstanding.
Transcript: Pediatrix Medical Group Q1 2026 Earnings Conference Call
Pediatrix Medical Group reported strong Q1 2026 results with adjusted EBITDA of $58 million, driven by top-line growth and strong pricing, despite a modest decline in same-unit volumes. The company reaffirmed its full-year 2026 adjusted EBITDA outlook of $280 to $300 million, attributing success to RCM cash collections, favorable payer mix, and increased patient acuity. Strategic initiatives include recruiting top physician leaders, expanding hospital partnerships, and rolling out a stock-based compensation program for clinician leaders.
Should Stronger Same‑Unit Revenue And Reaffirmed Outlook Require Action From Pediatrix Medical Group (MD) Investors?
Pediatrix Medical Group (MD) reported strong first-quarter 2026 results with sales of US$476.2 million and net income of US$29.57 million, exceeding prior year figures. This performance, driven by higher same-unit revenue and improved cash collections, led to a reaffirmed full-year adjusted EBITDA outlook. Investors should consider these positive trends against ongoing risks like reimbursement pressures and labor costs, while analysts provide varied fair value estimates for the stock.
Pediatrix Medical Group, Inc. (NYSE:MD) Q1 2026 Earnings Call Transcript
Pediatrix Medical Group (NYSE: MD) reported strong Q1 2026 results, exceeding earnings expectations with an EPS of $0.44 against an anticipated $0.37 and adjusted EBITDA of $58 million. The company reaffirms its full 2026 adjusted EBITDA outlook of $280 million to $300 million, despite some volume declines, driven by robust pricing and strategic investments in quality leadership and physician partnerships. Management highlighted the ongoing strength in pricing factors and cash flow usage for incentive payments and share repurchases.
Pediatrix Medical Group (NYSE: MD) grows Q1 2026 earnings and margin
Pediatrix Medical Group (NYSE: MD) reported strong first-quarter 2026 results, with net revenue increasing to $476.2 million and net income rising to $29.6 million. The company's diluted EPS grew to $0.36, and its operating margin improved to 8.7%. This growth was primarily driven by a 2.8% increase in same-unit revenue, recent acquisitions, and improved reimbursement conditions, while Pediatrix also repurchased 1.0 million shares and completed a maternal-fetal medicine acquisition.
Earnings rise in Q1 2026 at Pediatrix Medical Group (NYSE: MD)
Pediatrix Medical Group reported stronger Q1 2026 results, with net revenue increasing to $476.2 million and net income reaching $30 million. Diluted EPS rose to $0.36 and Adjusted EPS to $0.44, driven by improved reimbursement factors and operating leverage, despite a slight decline in same-unit patient volume. The company reaffirmed its full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million.
Earnings call transcript: Pediatrix Medical beats Q1 2026 estimates amid stock dip
Pediatrix Medical Group reported stronger-than-expected Q1 2026 earnings and revenue, with EPS of $0.44 against a forecast of $0.38, and revenue of $476 million against $465.68 million. Despite these positive financial results, the company's stock dipped 6.69% in pre-market trading, possibly due to broader market concerns. Pediatrix reaffirmed its full-year 2026 adjusted EBITDA guidance of $280 million to $300 million, emphasizing strategic initiatives such as enhanced clinical quality and expanded teleservices.
Should Stronger Same‑Unit Revenue And Reaffirmed Outlook Require Action From Pediatrix Medical Group (MD) Investors?
Pediatrix Medical Group reported stronger-than-expected Q1 2026 results with increased sales and net income, driven by improved same-unit revenue and cash collections. The company reaffirmed its full-year adjusted EBITDA outlook, suggesting confidence in its operational and financial performance despite ongoing challenges in reimbursement and labor costs. Investors are encouraged to look beyond the immediate positive results and evaluate long-term trends in contract negotiations and fair value estimates.
Should Stronger Same‑Unit Revenue And Reaffirmed Outlook Require Action From Pediatrix Medical Group (MD) Investors?
Pediatrix Medical Group (MD) reported stronger-than-expected first-quarter 2026 results, with increased sales and net income, driven by stronger same-unit revenue and improved cash collections. The company reaffirmed its full-year adjusted EBITDA outlook, suggesting management confidence, and a recent acquisition is expected to further support same-unit revenue growth. However, investors are advised to monitor potential risks from reimbursement trends and hospital contract negotiations despite the positive Q1 performance.
Pediatrix Medical Group: Q1 Earnings Snapshot
Pediatrix Medical Group (MD) reported a first-quarter profit of $29.6 million, or 36 cents per share, which adjusted to 44 cents per share, exceeding Wall Street expectations. The company also surpassed revenue forecasts, posting $476.2 million against an anticipated $467 million. These results indicate a strong financial performance for the quarter.
Pediatrix Medical Group: Q1 Earnings Snapshot
Pediatrix Medical Group, Inc. (MD) reported a first-quarter profit of $29.6 million, translating to 36 cents per share, or 44 cents per share when adjusted for one-time items. These results exceeded Wall Street expectations, with the company also announcing revenue of $476.2 million, surpassing analyst forecasts.
Earnings call transcript: Pediatrix Medical beats Q1 2026 estimates amid stock dip
Pediatrix Medical Group reported stronger-than-expected Q1 2026 earnings, with EPS of $0.44 and revenue of $476 million, surpassing analyst estimates. Despite these positive results, the company's stock dipped 6.69% in pre-market trading, reflecting broader market concerns. Pediatrix reaffirmed its full-year 2026 adjusted EBITDA guidance, emphasizing strategic initiatives in clinical quality and hospital partnerships.
Pediatrix Medical Group Reports First Quarter Results
Pediatrix Medical Group (NYSE: MD) reported strong first-quarter 2026 results, with earnings of $0.36 per share and adjusted EPS of $0.44, surpassing expectations. The company achieved net revenue of $476 million and Adjusted EBITDA of $58 million, driven by top-line growth and effective operational management. Pediatrix reaffirmed its full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million, highlighting its robust financial position and focus on strategic growth.
Pediatrix Medical in focus: Q1 earnings test growth strategy
Pediatrix Medical Group Inc. (NYSE:MD) is facing a critical test with its upcoming Q1 earnings report, as investors look to see if its expansion into maternal-fetal care can counteract persistent challenges like reimbursement pressures and staffing shortages. Analysts expect EPS of $0.38 and revenue of $465.7 million, with recent acquisitions and quality initiatives under scrutiny for their potential to drive sustainable margin expansion. The report will provide insight into whether the company's strategic adjustments are beginning to gain traction amidst an evolving healthcare landscape.
Pediatrix Medical Group (MD) Projected to Post Quarterly Earnings on Tuesday
Pediatrix Medical Group (NYSE:MD) is anticipated to report its Q1 2026 earnings before the market opens on Tuesday, May 5th, with analysts forecasting earnings of $0.37 per share and revenue of $465.6850 million. The company's previous quarter saw it miss consensus EPS estimates, reporting $0.50 against an expected $0.53, while revenue was $493.77 million. Institutional ownership of Pediatrix Medical Group stock is high at approximately 97.71%, and current analyst consensus rates the stock as "Hold" with an average price target of $21.33.
Pediatrix Medical Group, Inc. (NYSE:MD) Receives Consensus Recommendation of "Hold" from Brokerages
Pediatrix Medical Group, Inc. (NYSE:MD) has received a consensus "Hold" rating from seven brokerages, with an average one-year price target of $21.33. Institutional investors show high ownership, with Wasatch Advisors LP opening a new significant position. The company recently reported Q1 EPS of $0.50, missing estimates, but revenue of $493.8 million, beating expectations.
Pediatrix Medical Group, Inc. $MD Shares Acquired by Teacher Retirement System of Texas
Teacher Retirement System of Texas increased its stake in Pediatrix Medical Group (NYSE:MD) by 25.6% in the fourth quarter of 2025, acquiring an additional 62,446 shares and bringing its total holdings to 306,715 shares valued at $6.56 million. Other institutional investors also adjusted their holdings, with institutional investors and hedge funds now owning 97.71% of the stock. Pediatrix reported Q4 earnings of $0.50 EPS, missing consensus, and revenue of $493.77 million, slightly above estimates but down 1.7% year-over-year.
Total debt per share of Pediatrix Medical Group, Inc. – BMV:MD
This article provides a brief notice regarding the total debt per share of Pediatrix Medical Group, Inc. (BMV:MD). It indicates that the market is closed with no trades and points to financial data, news, and community sections for more information. The content primarily focuses on navigation and legal disclaimers rather than financial details.
Pediatrix Ties Up to Provide Better Maternal Care in Tennessee
Pediatrix Medical Group has partnered with a prominent health system in Memphis, Tennessee, to offer comprehensive maternal-fetal medicine services to high-risk pregnant patients. This collaboration aims to provide advanced care, including fetal diagnosis, monitoring, and treatment, thereby enhancing maternal care options in the region.
A Look At Pediatrix Medical Group (MD) Valuation After Recent Share Price Strength
Pediatrix Medical Group (MD) has seen its share price rise by 10% in the past month. Despite this, its fair value is estimated at $21.33, suggesting it is currently 7% overvalued based on a narrative model, even though its P/E ratio is lower than the US Healthcare industry average. Analysts predict annual revenue growth of 2.6% over the next three years, with earnings projected to reach $171.4 million by March 2029.
Pediatrix Medical Group 2026 First Quarter Conference Call/Webcast Scheduled for Tuesday, May 5, 2026
Pediatrix Medical Group (NYSE: MD) will host an investor conference call and webcast on Tuesday, May 5, 2026, at 9:00 a.m. ET to discuss its first-quarter 2026 operational results. A detailed press release will be issued on the morning of May 5, 2026, before the securities markets open. The webcast will be accessible via Pediatrix’s investor relations website, www.pediatrix.com/investors.
Pediatrix Medical Group stock (US59271J1051): Why mobile-first delivery is suddenly worth a closer l
Google's 2026 Discover Core Update is changing how investors receive updates on Pediatrix Medical Group (NYSE: MD) stock by prioritizing tailored, mobile-first delivery of financial content. This update leverages user activity to proactively deliver insights on neonatology and maternal-fetal medicine trends, patient volumes, and hospital partnerships directly to phone feeds. The shift benefits Pediatrix's data-rich business model by highlighting key financial metrics and operational efficiencies through structured, visual content, enabling faster detection of market opportunities and risks for investors.
Pediatrix Medical Group stock (US59271J1051): Why mobile-first delivery is suddenly worth a closer l
Google's 2026 Discover Core Update is revolutionizing how investors receive information on Pediatrix Medical Group (NYSE:MD) stock, prioritizing mobile-first and personalized insights directly in users' feeds. This shift provides proactive updates on key financial drivers, operational efficiencies, and market trends in neonatology and maternal-fetal medicine. The article emphasizes how Pediatrix's data-rich business model aligns well with Discover's algorithms, offering investors an edge through tailored, credible, and visually engaging content.
Is Pediatrix (MD) Trading Short-Term Revenue Beats For Higher Long-Term Cost Pressures?
Pediatrix Medical Group (MD) recently exceeded revenue expectations, but this was coupled with higher variable practice incentive compensation. This article examines how this revenue beat, achieved alongside increased incentive compensation, might impact Pediatrix’s investment narrative and risk profile, especially considering ongoing cost pressures and long-term concerns like declining U.S. birth rates. Analysts maintain a "Hold" rating despite the positive revenue news, highlighting a balanced risk-reward assessment.
Truist Raises Pediatrix Medical Group Price Target to $23
Truist has increased its price target for Pediatrix Medical Group (NYSE:MD) from $21 to $23, while maintaining a Hold rating. This adjustment reflects a generally optimistic outlook for the healthcare services sector, driven by a stable reimbursement landscape, consistent demand, and advancements in technology. Pediatrix Medical Group specializes in physician services including neonatal and maternal-fetal care.
Pediatrix Medical Group stock (US59271J1051): Why Google Discover changes matter more now
Google's 2026 Discover Core Update is fundamentally changing how investors receive financial news, moving from reactive search to proactive, personalized mobile content delivery. This shift significantly benefits companies like Pediatrix Medical Group (US59271J1051), by directly pushing relevant updates and analyses on its financial performance and strategic developments to retail investors' Google app feeds. The article emphasizes how this mobile-first approach, prioritizing fresh and visual content, enhances visibility and accelerates sentiment shifts for Pediatrix, potentially influencing investment decisions more rapidly than traditional channels.
Phocas Financial Corp. Acquires 103,328 Shares of Pediatrix Medical Group, Inc. $MD
Phocas Financial Corp. increased its stake in Pediatrix Medical Group (NYSE:MD) by 44.5% during Q4, purchasing an additional 103,328 shares to hold a total of 335,551 shares valued at approximately $7.18 million. Despite missing quarterly EPS estimates, Pediatrix Medical Group's revenue surpassed expectations, and institutional investors now own 97.71% of the company's stock. Analysts generally maintain a "Hold" rating for the stock, with an average price target of $20.20.
A Look Back at Healthcare Providers & Services Stocks’ Q4 Earnings: Pediatrix Medical Group (NYSE:MD) Vs The Rest Of The Pack
This article reviews the Q4 earnings season for healthcare providers and services stocks, focusing on Pediatrix Medical Group (NYSE:MD) and its peers. It highlights the sector's mixed performance, with revenues generally beating estimates but stock prices remaining relatively unchanged. The article details the financial results of Pediatrix Medical Group, RadNet, Chemed, Clover Health, and HCA Healthcare, noting individual company successes, misses, and stock reactions.
Pediatrix Medical Group, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance
Pediatrix Medical Group, Inc. (the company) has had its stock evaluation revised, with its stock priced at $21.45, showing a significant annual return of 58.19%, outperforming the S&P 500. While the company has shown resilience in the pharmaceuticals and biotechnology sector, particularly with an 8.66% return in the last month, it has faced challenges resulting in a 16.70% decline over five years. Technical indicators suggest a mixed outlook, with bullish trends in moving averages daily and Bollinger Bands weekly/monthly, but a mildly bearish MACD weekly.
